Cargando…
Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group
Patients with soft tissue sarcoma (STS), even after complete local disease control, often relapse locally or with distant metastases. This multicenter phase II study was conducted to evaluate the safety and efficacy of the combination of pegylated liposomal doxorubicin (PLD) and paclitaxel, as first...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409958/ https://www.ncbi.nlm.nih.gov/pubmed/15494721 http://dx.doi.org/10.1038/sj.bjc.6602148 |
_version_ | 1782155910006702080 |
---|---|
author | Bafaloukos, D Papadimitriou, C Linardou, H Aravantinos, G Papakostas, P Skarlos, D Kosmidis, P Fountzilas, G Gogas, H Kalofonos, C Dimopoulos, A M |
author_facet | Bafaloukos, D Papadimitriou, C Linardou, H Aravantinos, G Papakostas, P Skarlos, D Kosmidis, P Fountzilas, G Gogas, H Kalofonos, C Dimopoulos, A M |
author_sort | Bafaloukos, D |
collection | PubMed |
description | Patients with soft tissue sarcoma (STS), even after complete local disease control, often relapse locally or with distant metastases. This multicenter phase II study was conducted to evaluate the safety and efficacy of the combination of pegylated liposomal doxorubicin (PLD) and paclitaxel, as first-line treatment in patients with advanced STS. In all, 42 patients with locally advanced or metastatic STS, median age 54 years and median Eastern Cooperative Oncology Group performance status (PS) 1 were treated with PLD 45 mg m(−2) and paclitaxel 150 mg m(−2), every 28 days for a total of six cycles. Histological types included mainly leiomyosarcomas (43%), malignant fibrous histiocytomas (14%) and liposarcomas (12%). At study entry, 69% of patients had distant metastases. Overall response rate was 16%, including one complete (CR 2%) and six partial responses (PRs 14%), while an additional 14 patients had disease stabilization (SD 33%). At median follow-up 41.5 months, median time to progression (TTP) was 5.7 months with median overall survival (OS) 13.2 months. Grade 3–4 toxicities included neutropenia (17%), anaemia (15%), neurotoxicity (5%) and palmar–plantar erythrodysesthesia (9%). There were no treatment-related deaths. The combination of PLD and paclitaxel is a safe and well-tolerated regimen demonstrating modest efficacy as first-line treatment in patients with advanced STS. |
format | Text |
id | pubmed-2409958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-24099582009-09-10 Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group Bafaloukos, D Papadimitriou, C Linardou, H Aravantinos, G Papakostas, P Skarlos, D Kosmidis, P Fountzilas, G Gogas, H Kalofonos, C Dimopoulos, A M Br J Cancer Clinical Patients with soft tissue sarcoma (STS), even after complete local disease control, often relapse locally or with distant metastases. This multicenter phase II study was conducted to evaluate the safety and efficacy of the combination of pegylated liposomal doxorubicin (PLD) and paclitaxel, as first-line treatment in patients with advanced STS. In all, 42 patients with locally advanced or metastatic STS, median age 54 years and median Eastern Cooperative Oncology Group performance status (PS) 1 were treated with PLD 45 mg m(−2) and paclitaxel 150 mg m(−2), every 28 days for a total of six cycles. Histological types included mainly leiomyosarcomas (43%), malignant fibrous histiocytomas (14%) and liposarcomas (12%). At study entry, 69% of patients had distant metastases. Overall response rate was 16%, including one complete (CR 2%) and six partial responses (PRs 14%), while an additional 14 patients had disease stabilization (SD 33%). At median follow-up 41.5 months, median time to progression (TTP) was 5.7 months with median overall survival (OS) 13.2 months. Grade 3–4 toxicities included neutropenia (17%), anaemia (15%), neurotoxicity (5%) and palmar–plantar erythrodysesthesia (9%). There were no treatment-related deaths. The combination of PLD and paclitaxel is a safe and well-tolerated regimen demonstrating modest efficacy as first-line treatment in patients with advanced STS. Nature Publishing Group 2004-11-01 2004-10-19 /pmc/articles/PMC2409958/ /pubmed/15494721 http://dx.doi.org/10.1038/sj.bjc.6602148 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Bafaloukos, D Papadimitriou, C Linardou, H Aravantinos, G Papakostas, P Skarlos, D Kosmidis, P Fountzilas, G Gogas, H Kalofonos, C Dimopoulos, A M Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group |
title | Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group |
title_full | Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group |
title_fullStr | Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group |
title_full_unstemmed | Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group |
title_short | Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group |
title_sort | combination of pegylated liposomal doxorubicin (pld) and paclitaxel in patients with advanced soft tissue sarcoma: a phase ii study of the hellenic cooperative oncology group |
topic | Clinical |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409958/ https://www.ncbi.nlm.nih.gov/pubmed/15494721 http://dx.doi.org/10.1038/sj.bjc.6602148 |
work_keys_str_mv | AT bafaloukosd combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup AT papadimitriouc combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup AT linardouh combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup AT aravantinosg combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup AT papakostasp combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup AT skarlosd combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup AT kosmidisp combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup AT fountzilasg combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup AT gogash combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup AT kalofonosc combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup AT dimopoulosam combinationofpegylatedliposomaldoxorubicinpldandpaclitaxelinpatientswithadvancedsofttissuesarcomaaphaseiistudyofthehelleniccooperativeoncologygroup |